Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025Future Medicinal Chemistry

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMd Sadique HussainLZL. ZhangARAmita Joshi Rana

Discussion

Loading...

Member takes

Overview

Review explores novel HDAC-PROTACs in cancer therapy, highlighting treatment efficacy and selectivity challenges.

Key Points

  • HDAC-PROTACs provide a new strategy for cancer treatment by degrading HDACs through the ubiquitin-proteasome system.
  • Unlike traditional inhibitors, PROTACs need lower dosages while maintaining prolonged therapeutic effects in cancer models.
  • Advancements in PROTAC chemistry enable selective targeting of distinct HDAC classes with notable anti-cancer activity.
  • Despite progress, optimizing selectivity and enhancing bioavailability remain challenges for clinical applications.

Cite This Study

Hussain et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8ccc5ehttps://doi.org/10.1080/17568919.2025.2533113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery2026
  2. 2Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms2026 · 13 citations
  3. 3Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment2025 · 18 citations
  4. 4Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review2026 · 1 citations
  5. 5Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting Towards the Tumor-microenvironment: Development, Current State and Prospects2024 · 1 citations